There are 2789 resources available
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
627P - Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Presenter: Eugene Shenderov
Session: ePoster Display
628P - Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Presenter: Neal Shore
Session: ePoster Display
629P - Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy
Presenter: Brian Gonzalez
Session: ePoster Display
630P - Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
Presenter: Christian Gratzke
Session: ePoster Display
631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study
Presenter: Alejo Rodriguez-Vida
Session: ePoster Display
632P - Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)
Presenter: Benedito A Carneiro
Session: ePoster Display
671P - Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries
Presenter: Rachel Giles
Session: ePoster Display
672P - Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
Presenter: Giuseppe Procopio
Session: ePoster Display